Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of ecopipam in children and adolescents with Tourette syndrome
2019-000282-20Phase 2
- Sponsor
- Emalex Biosciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ecopipam in Tourette syndrome (TS), sponsored by Emalex Biosciences. Primary endpoints: Long-term safety and tolerability, Clinical and laboratory safety assessments and 1 more.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2019-000282-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000282-20.